Skip to main content
Clinical Trials/NCT06727929
NCT06727929
Active, not recruiting
Not Applicable

The Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid Dickkoff-1(Dkk-1) and Secreted Frizzled Related Protein 5 (sFRP5) Levels

Cumhuriyet University1 site in 1 country99 target enrollmentMarch 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Periodontal Inflammation
Sponsor
Cumhuriyet University
Enrollment
99
Locations
1
Primary Endpoint
Dkk-1 and sFRP5 levels at baseline and after periodontal treatment
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

Periodontitis is a condition that is defined by microbial-associated, host-induced inflammation, which ultimately results in the loss of periodontal attachment.Periodontal clinical parameters are the most reliable indicators of periodontal disease; however, they provide information about past tissue destruction and are insufficient for predicting future periodontal disease activity. Therefore, evaluation of Dickkopf-1 (Dkk-1) and secreted Frizzled related protein 5 (sFRP5), which are Wnt signaling pathway antagonists, in periodontal inflammation may be a focus of interest. A total of 99 individuals, 44 male and 55 female, participated in our study and were divided into three groups as periodontally healthy, gingivitis and periodontitis. Non-surgical periodontal treatment was applied to the disease groups. Dkk-1 and sFRP5 were evaluated in gingival crevicular fluid (GCF) at the baseline and after periodontal treatment.

Detailed Description

The participants were divided into three groups in accordance with their periodontal status according to the 2017 World Workshop on the classification of periodontal diseases : Periodontally healthy (group H, n = 33, probing depth (PD) ≤3 mm, fullmouth bleeding scores; bleeding on probing (BOP) % \<10, no clinical attachment levels (CAL) and radiologic bone loss), gingivitis (group G, n = 33 PD ≤3 mm, % BOP \>30, no CAL(due to periodontal disease) and radiologic bone loss), Stage 3 Grade B periodontitis (group P, n = 33, These individuals had a minimum of two non-adjacent teeth with sites with PD ≥6 mm, CAL ≥5 mm, BOP ≥30%, tooth loss due to periodontitis ≤4 teeth, the alveolar bone loss at radiographs extending to middle or apical third of the root, the presence of consistent amounts of plaque biofilm/calculus deposits commensurate with the severity of periodontal tissue breakdown, the proportion of percentage bone loss to age values were between 0.25 and 1). Panoromic and periapical radiographic examination was also performed for the diagnosis of periodontitis. Periodontal status of each individual included in the study was determined by measuring plaque index (PI), gingival index (GI), PD, clinical attachment level (CAL) and bleeding of probing (BOP). PD and CAL were measured on six sites (mesio-buccal/ facial, mid-buccal/facial, disto-buccal/facial, mesio-lingual/palatinal, mid-lingual/palatinal, disto-lingual/palatinal) of the teeth in baseline and after periodontal treatment. Bleeding was observed up to 10 sec after the examination of probing depth and BOP score was calculated as the number of BOP-positive sites was divided the number of total sites, after multiplied with 100. Panoramic and periapical radiographs were used to determine the alveolar bone loss. All clinical measurements were recorded using a standard Williams periodontal probe. Within 2 weeks from the screening visit, phase 1 periodontal treatment/scaling and root planing under local anesthesia using manual instruments and ultrasonic devices in a single appointment were performed and oral hygiene instructions were given to all participants with periodontitis by a single calibrated periodontist. In gingivitis and periodontally healthy groups, phase 1 periodontal treatment and oral hygiene education were given to each one. All periodontal clinical measurements recorded and gingival crevicular fluid (GCF) samples collection were at baseline and the 6-8 th week after the periodontal treatment in patients with G and P group and at one time point (baseline) in H group.

Registry
clinicaltrials.gov
Start Date
March 1, 2024
End Date
February 1, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sukran Acipinar

Ass.Prof.

Cumhuriyet University

Eligibility Criteria

Inclusion Criteria

  • Being between 20-50 years old
  • Meeting the criteria for the working groups

Exclusion Criteria

  • having any systemic or metabolic diseases or insturition of effected bone metabolism,
  • having bruksizm habits,
  • pregnant or lactating,
  • received periodontal/peri-implant treatment within the last 6 months,
  • the history of antibiotics or antiinflamatuars use regularly within the last 6 months,
  • having \< 20 teeth (except for 3rd molars),
  • smokers or consumed alcohol.

Outcomes

Primary Outcomes

Dkk-1 and sFRP5 levels at baseline and after periodontal treatment

Time Frame: 6-8 weeks

Dkk-1 and sFRP5 levels assessed by ELISA in GCF at baseline and after non-surgical periodontal treatment were the primary outcome measures.Dkk-1 and sFRP5 will be measured by ELISA technique according to the manufacturer's instructions. The sensitivity value for Dkk-1 and sFRP5 is 0.056 ng/mL and 0.059 ng/mL, respectively. Optical densities will be taken at 450 nm wavelength, and standard concentrations and corresponding optical density values and sample optical density values will be recorded. The standard curve will be drawn according to the optical densities and concentrations of standards, and the concentrations of all samples will be calculated by the linear regression equation of the obtained standard curve.Dkk-1 and sFRP5 total amount will be given in ng unit.

Secondary Outcomes

  • Gingival Crevicular Fluid (GCF)Volume at baseline and after periodontal treatment(6-8 weeks)
  • Gingival index (GI) at baseline and after periodontal treatment(6-8 weeks)
  • Bleeding on probing (BOP) percentage at baseline and after periodontal treatment(6-8 weeks)
  • Probing depth (PD)at baseline and after periodontal treatment(6-8 weeks)
  • Plaque index (PI) at baseline and after periodontal treatment(6-8 weeks)
  • Clinical attachment levels (CAL) at baseline and after periodontal treatment(6-8 weeks)

Study Sites (1)

Loading locations...

Similar Trials